Long Acting Lipoglycopeptides: Antibiotic Friend or Foe?

<p>Andrew J. Jatis, PharmD (<a href='https://twitter.com/jatis_rx'>Twitter: @jatis_rx</a>) reviews the pharmacology and drug characteristics of dalbavancin and oritavancin, describes current literature assessing the safety and efficacy of FDA approved and off-label indications for lipoglycopeptide use in clinical practice and discusses pharmacoeconomic implications of lipoglycopeptide use in clinical practice.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>